Brief: Amphastar Pharmaceuticals- Nanjing Pharmaceuticals Enters Supply Agreement With Nanjing Letop Biotechnology On March 3 - SEC Filing
06/03/2026 21:50
March 6 (Reuters) - Amphastar Pharmaceuticals Inc AMPH.O: AMPHASTAR PHARMACEUTICALS- NANJING PHARMACEUTICALS ENTERS SUPPLY AGREEMENT WITH NANJING LETOP BIOTECHNOLOGY ON MARCH 3- SEC FILING AMPHASTAR PHARMACEUTICALS INC - SUPPLY AGREEMENT EFFECTIVE FOR FIVE YEARS WITH PAYMENTS IN CHINESE YUAN - SEC FILING AMPHASTAR PHARMACEUTICALS: ON MARCH 3, CO & NANJING HANXIN PHARMACEUTICAL TECHNOLOGY ENTERED INTO AMENDMENT TO CONTRACT RESEARCH AGREEMENT AMPHASTAR PHARMACEUTICALS: PURSUANT TO AMENDMENT, CO TO USE RESEARCH CELL BANKS THAT HANXIN DEVELOPS TO MAKE MASTER CELL BANKS FOR AMP-105 Further company coverage: AMPH.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Amphastar Pharmaceuticals,
See all newsU.S. RESEARCH ROUNDUP-Airbnb, HII, Tesla
Amphastar Q1 revenue and adjusted EPS miss estimates
Brief: Amphastar Pharmaceuticals Q1 EPS USD 0.14
Brief: Amphastar Pharmaceuticals Inc - Authorizes $50 Million Increase To Share Buyback Program On March 12, 2026 - SEC Filing
Brief: Amphastar Pharmaceuticals- Nanjing Pharmaceuticals Enters Supply Agreement With Nanjing Letop Biotechnology On March 3 - SEC Filing